Bill Sponsor
House Bill 4322
116th Congress(2019-2020)
Expanding Cannabis Research and Information Act
Introduced
Introduced
Introduced in House on Sep 12, 2019
Overview
Text
Introduced
Sep 12, 2019
Latest Action
Oct 2, 2019
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
4322
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Democrat
Florida
Democrat
California
Democrat
Connecticut
Republican
Florida
House Votes (0)
Senate Votes (0)
No House votes have been held for this bill.
Summary

Expanding Cannabis Research and Information Act

This bill changes marijuana from a Schedule I to a Schedule III controlled substance, which allows it to be dispensed, subject to certain limitations, for accepted medical uses with a written or oral prescription.

The bill also requires the National Institutes of Health (NIH) to collaborate with specified agencies to develop a national cannabis research agenda that must address (1) the therapeutic benefits of cannabis, (2) how it effects specified populations, (3) its long-term effects, (4) clinically appropriate methods to deliver it to the body, and (5) other public safety considerations. Additionally, the bill directs NIH to designate centers of excellence in cannabis research at institutions of higher education to conduct interdisciplinary research about biomedical, behavioral, and social issued related to cannabis.

Further, the Centers for Disease Control and Prevention must work with other agencies to collect population-wide data about cannabis use, including (1) demographic factors, (2) health outcomes, (3) health care utilization rates, (4) product variety, (5) delivery methods, and (6) other relevant health information.

Text (1)
September 12, 2019
Actions (4)
10/02/2019
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
09/13/2019
Referred to the Subcommittee on Health.
09/12/2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
09/12/2019
Introduced in House
Public Record
Record Updated
Nov 1, 2022 1:50:02 PM